{"protocolSection":{"identificationModule":{"nctId":"NCT03284463","orgStudyIdInfo":{"id":"NFEC-2017-130"},"organization":{"fullName":"Nanfang Hospital, Southern Medical University","class":"OTHER"},"briefTitle":"Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism","officialTitle":"Safety and Efficacy of Glibenclamide Combined With Rt-PA in Treating Acute Ischemic Stroke: a Prospective, Randomized, Double-blind, Placebo-control, Multi-center Study","acronym":"SE-GRACE"},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-01-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-08-28","type":"ACTUAL"},"completionDateStruct":{"date":"2023-05-28","type":"ACTUAL"},"studyFirstSubmitDate":"2017-09-14","studyFirstSubmitQcDate":"2017-09-14","studyFirstPostDateStruct":{"date":"2017-09-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-06-09","lastUpdatePostDateStruct":{"date":"2023-06-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Nanfang Hospital, Southern Medical University","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is designed to evaluate the safety and efficacy of oral glibenclamide in acute ischemic stroke patients who under intravenous rt-PA thrombolysis."},"conditionsModule":{"conditions":["Acute Stroke"],"keywords":["acute ischemic stroke","glibenclamide","rt-PA","blood-brain barrier","brain edema"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":306,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Glibenclamide","type":"ACTIVE_COMPARATOR","description":"Glibenclamide Tablets","interventionNames":["Drug: Glibenclamide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo for Glibenclamide","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Glibenclamide","description":"Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.","armGroupLabels":["Glibenclamide"]},{"type":"DRUG","name":"Placebo","description":"Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Functional outcome: The proportion of mordified Rankin Scale of 0 to 2 points","description":"The proportion of mordified Rankin Scale of 0 to 2 points at 90 days","timeFrame":"90 days after the stroke onset"}],"secondaryOutcomes":[{"measure":"Early improvement: The proportion of NIHSS decreased ≥ 4 points","description":"The proportion of NIHSS decreased ≥ 4 points at 7 days","timeFrame":"7 days after the stroke onset"},{"measure":"Hemorrhagic transformation: The proportion of parenchymal hemorrhagic transformation in cranial CT","description":"The proportion of parenchymal hemorrhagic transformation in cranial CT within 96 hours","timeFrame":"96 hours after the stroke onset"},{"measure":"Midline shift: The proportion of midline shift ≥ 6 mm in cranial CT","description":"The proportion of midline shift ≥ 6 mm in cranial CT within 96 hours","timeFrame":"96 hours after the stroke onset"},{"measure":"Functional outcome 2: The modified Rankin Scale distribution","description":"The modified Rankin Scale distribution at 90 days","timeFrame":"90 days after the stroke onset"},{"measure":"Functional outcome 3: The proportion of Barthel Index of 60-100 points","description":"The proportion of Barthel Index of 60-100 points","timeFrame":"90 days after the stroke onset"},{"measure":"Functional outcome 4: The proportion of IQCODE of ≤ 3.40","description":"The proportion of Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) of ≤ 3.40 at 6 months and 1 year after the stroke onset","timeFrame":"6 months and 1 year after the stroke onset"},{"measure":"Blood-brain barrier: The serum concentration of MMP-9","description":"The serum concentration of MMP-9 at baseline, and at 24, 48, and 72 h","timeFrame":"Baseline, 24, 48, and 72 hours after the stroke onset"}],"otherOutcomes":[{"measure":"Mortality","description":"The mortality at 90 days","timeFrame":"90 days after the stroke onset"},{"measure":"Early neurological deterioration","description":"The ratio of neurological deterioration (NIHSS increased ≥ 4 points) within 24 hours after the onset","timeFrame":"24 hours after the stroke onset"},{"measure":"Hypoglycemia","description":"The incidence of hypoglycemia (random blood glucose \\< 3.9 mmol/L)","timeFrame":"5 days after the stroke onset"},{"measure":"Cardiac events","description":"The incidence of cardiac events in cardiac examination (ECG, echocardiography)","timeFrame":"30 days after the stroke onset"},{"measure":"Pulmonary infection","description":"The incidence of pulmonary infection","timeFrame":"7 days within the stroke onset"},{"measure":"AEs and SAEs","description":"The incidence of adverse event and serious adverse event","timeFrame":"30 days after the stroke onset"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of acute ischemic stroke in the MCA territory (PCA and/or ACA territory involvement in addition to primary MCA territory stroke is acceptable)\n* Aged ≥18 and ≤74 years\n* A baseline NIHSS score between 4 to 25\n* Intravenous rt-PA thrombolysis conducted within 4.5 hours after stroke onset, if known, or the time last seen well \\[termed \"time last known at neurologic baseline\" (TLK@B)\\]\n* The time to the start of administration of Study Drug must be ≤10 h after time of symptom onset or TLK@B\n* Informed consent was signed by the subject or the legal representative\n\nExclusion Criteria:\n\n* Prior to stroke, significant disability exists, with modified Rankin Scale \\>1 point\n* With medical history or evidence of cerebral hemorrhage, subarachnoid hemorrhage, arteriovenous malformation, cerebral aneurysm or brain tumor\n* With clinical or imaging evidence of contralateral cerebral infarction which is believed to have influence on the patient outcome by the investigators\n* With clinical or imaging evidence of occlusion in vertebral or basilar artery\n* With clinical evidence of brain herniation, e.g., one or two dilated, fixed pupils; unconsciousness (i.e., C2 on item 1a on the NIHSS); and/or loss of other brainstem reflexes, attributable to edema or herniation according to the investigator's judgment\n* With gastrointestinal bleeding and instable hemodynamics or other causes that force the patient to stop nutritional support\n* Renal disorder from the patient's history (e.g., dialysis) or eGFR of \\<60 mL/min/1.73 m2\n* Severe liver disease, or ALT \\>3 times upper limit of normal or bilirubin \\>2 times normal (subjects may be randomized if liver function tests have been drawn but are not yet available and the subject has no known history of liver disease; however treatment with Study Drug cannot commence until liver function tests are available and indicate ALT \\>3 times upper limit of normal and bilirubin \\>2 times upper limit of normal)\n* Blood glucose \\<3.0 mmol/L at enrollment or immediately prior to administration of Study Drug, or a clinically significant history of hypoglycemia\n* Acute ST elevation myocardial infarction, and/or acute decompensated heart failure, and/or Tc \\> 520 ms, and/or known history of cardiac arrest (PEA, VT, VF, asystole), and/or admission for an acute coronary syndrome, myocardial infarction, or coronary intervention within the past 3 months\n* Known sulfonylurea treatment within 7 days. Sulfonylureas include glyburide/glibenclamide; glibenclamide plus metformin; Xiaoke Pill (a Chinese patent medicine with main effective constituent of glibenclamide); glimepiride; repaglinide; nateglinide; glipizide; gliclazide; tolbutamide; glibornuride\n* Known treatment with bosentan within 7 days\n* Known allergy to sulfa or specific allergy to sulfonylurea drugs\n* Known G6PD enzyme deficiency\n* Pregnant women. Women must be either postmenopausal (as confirmed by the LAR), permanently sterilized or, if ≤50 years old must have a negative test for pregnancy obtained before enrollment\n* Breast-feeding women who do not agree (or their LAR does not agree) to stop breastfeeding during Study Drug infusion and for 7 days following the end of Study Drug infusion\n* Patients already enrolled in a non-observation-only stroke study, or with life-expectancy \\<6 months not related to current stroke, or those unlikely to be compliant with follow up\n* Patients currently receiving an investigational drug\n* Mentally incompetent (prior to qualifying stroke) patients and wards of the state\n* Patients who, in the opinion of the investigator, are not suitable for the study (reason to be documented)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"74 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Suyue Pan, M.D., Ph.D.","affiliation":"Department of Neurology, Nanfang Hospital, Southern Medical University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Huadu District People's Hospital of Guangzhou","city":"Guangzhou","state":"Guangdong","zip":"510515","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Nanfang Hospital of Southern Medical University","city":"Guangzhou","state":"Guangdong","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Heyuan People's Hospital","city":"Heyuan","state":"Guangdong","country":"China","geoPoint":{"lat":23.73333,"lon":114.68333}},{"facility":"Maoming People's Hospital","city":"Maoming","state":"Guangdong","country":"China","geoPoint":{"lat":21.65,"lon":110.9}},{"facility":"Maoming Traditional Chinese Medical Hospital","city":"Maoming","state":"Guangdong","country":"China","geoPoint":{"lat":21.65,"lon":110.9}},{"facility":"Hainan Provincial Hospital of Traditional Chinese Medicine","city":"Haikou","state":"Hainan","zip":"570100","country":"China","geoPoint":{"lat":20.04583,"lon":110.34167}},{"facility":"Haikou People's Hospital","city":"Haikou","state":"Hainan","zip":"570208","country":"China","geoPoint":{"lat":20.04583,"lon":110.34167}},{"facility":"The First Affiliated Hospital of Wenzhou Medical University","city":"Wenzhou","state":"Jiangsu","zip":"325000","country":"China","geoPoint":{"lat":27.99942,"lon":120.66682}}]},"referencesModule":{"references":[{"pmid":"32527232","type":"DERIVED","citation":"Huang K, Ji Z, Wu Y, Huang Y, Li G, Zhou S, Yang Z, Huang W, Yang G, Weng G, Chen P, Pan S. Safety and efficacy of glibenclamide combined with rtPA in acute cerebral ischemia with occlusion/stenosis of anterior circulation (SE-GRACE): study protocol for a randomized controlled trial. BMC Neurol. 2020 Jun 11;20(1):239. doi: 10.1186/s12883-020-01823-z."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M7474","name":"Embolism","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","relevance":"LOW"},{"id":"M7347","name":"Edema","relevance":"LOW"},{"id":"M4896","name":"Brain Edema","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000005905","term":"Glyburide"}],"ancestors":[{"id":"D000007004","term":"Hypoglycemic Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","relevance":"LOW"},{"id":"M8707","name":"Glyburide","asFound":"Pre-exposure Prophylaxis","relevance":"HIGH"},{"id":"M9744","name":"Hypoglycemic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Hypo","name":"Hypoglycemic Agents"}]}},"hasResults":false}